3B Blackbio DX Ltd
₹ 1,579
-0.74%
13 Jun
- close price
About
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
Key Points
- Market Cap ₹ 1,356 Cr.
- Current Price ₹ 1,579
- High / Low ₹ 2,350 / 990
- Stock P/E 28.5
- Book Value ₹ 318
- Dividend Yield 0.19 %
- ROCE 25.5 %
- ROE 19.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 139% CAGR over last 5 years
- Debtor days have improved from 179 to 142 days.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 | 18 | 16 | 13 | 16 | 12 | 14 | 14 | 16 | 59 | 71 | 91 | |
| 20 | 17 | 15 | 12 | 14 | 12 | 14 | 16 | 17 | 30 | 36 | 41 | |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 0 | -0 | -1 | -1 | 30 | 35 | 50 |
| OPM % | 6% | 7% | 7% | 8% | 7% | 4% | -2% | -8% | -8% | 50% | 50% | 55% |
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 10 | 7 | 12 | 15 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 36 | 46 | 64 |
| Tax % | 14% | 21% | 23% | 14% | 9% | 2% | 0% | 18% | 5% | 26% | 26% | 26% |
| 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 26 | 34 | 48 | |
| EPS in Rs | 0.59 | 0.34 | 0.30 | 0.36 | 0.81 | 0.67 | 0.81 | 2.29 | 10.67 | 35.19 | 39.86 | 55.41 |
| Dividend Payout % | 0% | 0% | 0% | 83% | 61% | 74% | 86% | 392% | 98% | 8% | 8% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 46% |
| 3 Years: | 80% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 71% |
| 5 Years: | 139% |
| 3 Years: | 81% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 70% |
| 5 Years: | 55% |
| 3 Years: | 66% |
| 1 Year: | 43% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 5 | 5 | 9 | 9 | 13 | 15 | 16 | 188 | 219 | 264 |
| 6 | 7 | 7 | 8 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | |
| 7 | 7 | 6 | 5 | 5 | 5 | 4 | 4 | 5 | 16 | 21 | 24 | |
| Total Liabilities | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 214 | 250 | 297 |
| 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 7 | 7 | 6 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 4 | 4 | 102 | 128 | 167 |
| 21 | 22 | 21 | 21 | 22 | 23 | 22 | 23 | 25 | 105 | 116 | 124 | |
| Total Assets | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 214 | 250 | 297 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 1 | 0 | -1 | 0 | 1 | 3 | 8 | 21 | 28 | 44 | |
| -0 | -0 | -0 | 0 | -0 | -0 | -2 | -0 | -2 | -8 | -20 | -34 | |
| 0 | -0 | -1 | -0 | 1 | -0 | 1 | -2 | -6 | -3 | -4 | -3 | |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 1 | 0 | 10 | 5 | 8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 217 | 271 | 303 | 371 | 332 | 426 | 382 | 358 | 337 | 206 | 188 | 142 |
| Inventory Days | 106 | 128 | 121 | 190 | 108 | 176 | 116 | 88 | 81 | 154 | 144 | 122 |
| Days Payable | 175 | 204 | 190 | 237 | 115 | 156 | 108 | 95 | 108 | 63 | 65 | 24 |
| Cash Conversion Cycle | 148 | 196 | 234 | 323 | 326 | 447 | 390 | 351 | 311 | 297 | 267 | 240 |
| Working Capital Days | 222 | 282 | 331 | 428 | 410 | 549 | 494 | 447 | 431 | 255 | 225 | 174 |
| ROCE % | 7% | 6% | 5% | 6% | 6% | 4% | 4% | 9% | 34% | 32% | 22% | 26% |
Documents
Announcements
-
Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended 31-03-2025
21h - Approved FY25 audited results; recommended 40% final dividend; appointed secretarial and internal auditors.
-
Newspaper Publicatiob
4 Jun - Notice on transfer of unclaimed dividends/shares to IEPF as per regulatory requirements.
-
Letter For Transfer Of Shares To Investor Education And Protection Fund (IEPF)
3 Jun - Notice to shareholders about transfer of shares with unpaid dividends to IEPF by Oct 1, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 May - Submission of Advertisement clipping of the Extract of the Audited Standalone and Consolidated Financial Result of the company for the Quarter and Year ended 31-03-2025
-
Appointment Of Secretarial Auditor
28 May - Approved audited FY25 results; recommended 40% final dividend; appointed secretarial and internal auditors.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Nov 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jul 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit